AndroGel Cost in Alaska 2026: Cash Pay, Insurance, and Compounded Alternatives

What Is the Cash-Pay Price of AndroGel in Alaska in 2026?

The AbbVie manufacturer list price for AndroGel 1.62% sits at approximately $510 per month at Alaska retail pharmacies in 2026, consistent with national average wholesale pricing. Without insurance or a discount program, that figure is what most patients pay at the counter. GoodRx and similar aggregators may show slightly lower rates at specific Anchorage or Fairbanks chains, but savings rarely drop below $430 to $460 for brand-name AndroGel in-state.

AndroGel 1% (the original formulation, FDA-approved in 2000) [1] shares a similar price band. Patients who need 50 mg of testosterone daily are typically prescribed AndroGel 1.62% at 40.5 mg (two pump actuations), with titration up to 81 mg based on serum total testosterone drawn 2 to 8 hours after application, per the FDA prescribing label. [1]

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men states: "We suggest initiating testosterone therapy with any of the available formulations, considering patient preference, pharmacokinetics, and cost." [2] Cost is a named variable in guideline decision-making, which means clinicians are expected to discuss the $510 cash-pay figure with uninsured Alaskan patients before writing the prescription.

Cash-pay prices are higher in rural Alaska because the supply chain adds freight costs to already-thin pharmacy margins. Patients in Juneau, Sitka, or Kodiak consistently report prices at the upper end of the $480 to $530 range. [3]

For context, the T-Trials (N=788), the most rigorously designed multi-center trial of testosterone therapy in older men, used testosterone gel as the study formulation, confirming clinical efficacy across sexual function, bone density, and anemia endpoints. [4] Efficacy is not in dispute. Affordability is the obstacle.

Does Alaska Medicaid Cover AndroGel?

Alaska Medicaid does not cover AndroGel or generic testosterone gel for male hypogonadism in 2026. The Alaska Division of Health Care Services Preferred Drug List (PDL) excludes brand-name testosterone gels from covered outpatient pharmacy benefits for this indication. [5]

This matters most for the roughly 16% of Alaska adults enrolled in Medicaid. Prior authorization pathways exist on paper, but approvals for AndroGel specifically are rare based on claims data from comparable state Medicaid programs. [6] Testosterone cypionate injectable (a Schedule III controlled substance like AndroGel) is covered on the Alaska Medicaid PDL at a substantially lower cost, making it the de-facto Medicaid-covered testosterone option for eligible men. [5]

Patients who are dually eligible for Medicare and Medicaid may find Part D formulary coverage of generic testosterone gel through certain Medicare Advantage plans, but plan-level formularies vary by carrier and change annually. Always confirm formulary status for the current benefit year directly with the plan.

A 2021 JAMA Internal Medicine analysis found that testosterone therapy prescribing rates vary significantly by insurance status, with uninsured and Medicaid-enrolled men 34% less likely to receive guideline-concordant monitoring. [7] The cost barrier is directly linked to care gaps.

Which Private Insurance Plans Cover AndroGel in Alaska?

Commercial insurance coverage of AndroGel in Alaska is inconsistent across carriers. Premera Blue Cross, the largest commercial insurer in the state, lists testosterone gel products on its specialty tier with a typical member cost-share of $80 to $150 per month after meeting the deductible, depending on the specific plan design. [8] Moda Health and Providence Health Plan apply similar specialty-tier cost-sharing structures.

Most plans require prior authorization documenting two morning serum total testosterone levels below 300 ng/dL (the threshold used by the American Urological Association 2018 guideline) [9] along with clinical signs of hypogonadism. Labs drawn before 10 AM and at least one week apart typically satisfy medical-necessity criteria.

Step therapy requirements are common. Carriers frequently require a 90-day trial of a lower-cost testosterone formulation (usually testosterone cypionate injection at roughly $30 to $60 per month) before approving AndroGel. Patients who fail injectable therapy or have a documented contraindication to injections have a stronger appeal case.

The FDA's MedWatch database shows no Alaska-specific dispensing restrictions on testosterone gel beyond federal Schedule III requirements. [10] Insurance denial, not legal prohibition, is the primary access barrier.

HealthRX Prior Authorization Decision Framework for Alaska AndroGel Patients

1. Confirm two morning total testosterone values <300 ng/dL, at least one week apart, both drawn before 10 AM.
2. Document at least two clinical signs of hypogonadism (low libido, fatigue, reduced muscle mass, depressed mood).
3. Check plan formulary for generic testosterone gel (1% or 1.62%) as a covered alternative to brand AndroGel.
4. If step therapy required, initiate testosterone cypionate 200 mg/mL injection every 1 to 2 weeks and document any adverse effects or patient-specific barriers (needle phobia, self-injection inability).
5. Submit PA with both lab values, symptom documentation, and step-therapy record.
6. If denied, use the AbbVie myAbbVie Assist copay card as a bridge while appealing.

How Does Compounded Testosterone Gel Work in Alaska?

Licensed 503A compounding pharmacies operating in Alaska can legally prepare compounded testosterone gel for individual patients who have a valid prescription from a licensed prescriber. [11] This is distinct from 503B outsourcing facilities, which compound for hospital or clinic bulk orders. For individual retail patients, 503A is the applicable pathway.

Compounded testosterone gel at a licensed Alaska 503A pharmacy runs approximately $120 per month for a supply equivalent to 1% testosterone gel, 50 mg daily. That is a 76% reduction from the $510 brand list price.

The FDA does not approve compounded formulations and does not verify their potency, sterility, or bioavailability against the branded product. [12] The American Urological Association notes that compounded testosterone products "have not been demonstrated to be equivalent to FDA-approved products in terms of pharmacokinetics or clinical outcomes." [9] Patients choosing compounded gel should understand this tradeoff.

Prescribers in Alaska must write compounded testosterone prescriptions with a specific patient name; pharmacies cannot prepare it for general inventory under 503A rules. [11] Telehealth prescribers licensed in Alaska can issue these prescriptions legally, provided they comply with Alaska Statute 08.64 governing telemedicine practice.

Serum testosterone monitoring is the same regardless of formulation: total testosterone drawn 2 to 8 hours after gel application, targeting a mid-normal range of 400 to 700 ng/dL per most clinical protocols. [2] Dose adjustment for compounded gel follows the same logic as branded AndroGel, though the compounding pharmacy sets the concentration (typically 1% or 2%).

A 2022 Endocrine Practice review found that compounded testosterone formulations showed potency variability of up to 30% across samples tested. [13] That variability is the main clinical risk argument for branded products.

What Is the AbbVie myAbbVie Assist Savings Card?

AbbVie offers two programs: the myAbbVie Assist copay card for commercially insured patients and the myAbbVie Assist patient assistance program (PAP) for uninsured patients who meet income criteria.

For commercially insured Alaskans, the copay card may reduce out-of-pocket cost to $0 per month on eligible prescriptions. [14] Eligibility requires commercial insurance (Medicaid, Medicare Part D, and TRICARE enrollees are excluded by federal law). Enrollment is completed online at AbbVie's patient support site or through the prescribing clinic.

The PAP provides free AndroGel to uninsured patients with household income at or below 400% of the federal poverty level (approximately $58,320 for a single individual in 2026). [14] Applications require income verification and a prescriber signature. Processing time is 2 to 4 weeks. A 90-day supply is typically dispensed at once through a mail-order pharmacy.

Patients in rural Alaska who cannot access a retail pharmacy may find the PAP mail-order pathway more practical than any retail discount option. The 90-day supply format also reduces the frequency of supply interruptions common in Alaska's bush communities.

AbbVie's programs do not cover compounded testosterone. They are specific to branded AndroGel 1% and 1.62% dispensed at licensed retail or specialty pharmacies.

Can a Telehealth Provider Prescribe AndroGel in Alaska?

Yes. Telehealth prescribing of AndroGel is legal in Alaska as of 2026, provided the prescriber holds an active Alaska medical license and complies with state telemedicine standards under Alaska Statute 08.64. [15] The prescriber-patient relationship must be established through a synchronous audio-video visit before a controlled substance prescription can be issued, consistent with the DEA's telemedicine rules for Schedule III substances.

The Ryan Haight Online Pharmacy Consumer Protection Act historically required an in-person visit before prescribing any Schedule III drug via telemedicine. A 2023 DEA proposed rule created a special registration pathway for telemedicine prescribing of controlled substances, including testosterone, that may allow audio-video visits to substitute for in-person evaluation in registered practices. [16] Alaska prescribers using this pathway must register with the DEA's Telemedicine Prescribing registry as rules finalize.

In practical terms, most HealthRX-affiliated providers complete an initial video consultation, review lab results the patient submits in advance (or order them through a local draw site), and issue the AndroGel or compounded testosterone prescription electronically to a pharmacy of the patient's choice.

A 2023 JAMA Network Open study (N=5,390) found that patients using telehealth for testosterone therapy had equivalent 12-month testosterone levels and adverse-event rates compared to those treated in traditional office settings. [17] Remote prescribing does not compromise monitoring quality when labs are tracked correctly.

What Are the Cheapest Ways to Get AndroGel in Alaska?

The cost hierarchy from lowest to highest runs roughly as follows.

AbbVie PAP (uninsured, income-eligible): $0 per month. This is the lowest possible cost for qualifying patients.

Compounded 503A testosterone gel: approximately $120 per month. Legal, accessible via telehealth prescription, and widely available through Alaska-licensed compounding pharmacies that ship within the state.

GoodRx or similar coupon at retail: approximately $430 to $460 per month for brand AndroGel 1.62% at major Anchorage chains. Coupons cannot stack with insurance benefits.

Commercial insurance with AbbVie copay card: $0 to $80 per month depending on plan tier. The copay card offsets the member cost-share in most cases.

Commercial insurance without copay card: $80 to $150 per month on specialty tier.

Cash pay without any program: approximately $510 per month.

A 2020 Health Affairs study found that cost-related non-adherence to testosterone therapy was reported by 22% of patients with annual household incomes below $40,000. [18] In Alaska, where median household income is approximately $82,000 but rural communities cluster well below that figure, cost-related gaps are a documented clinical risk.

Generic testosterone gel (1%) is FDA-approved and available at some Alaska pharmacies for $80 to $120 per month cash-pay, making it another mid-range option that preserves FDA oversight while cutting costs relative to brand AndroGel.

How Is AndroGel Dosed and Monitored?

AndroGel 1.62% starts at 40.5 mg (two pump actuations or two packets) applied to the upper arms or shoulders once daily. The FDA-approved titration schedule allows dose increases to 81 mg or reductions to 20.25 mg based on serum testosterone levels. [1] Levels should be checked 2 to 8 hours after application on day 14 and day 28, then every 6 to 12 months once stable.

Target serum total testosterone for replacement therapy is 400 to 700 ng/dL by most clinical protocols. [2] Values above 1 to 000 ng/dL prompt dose reduction. Hematocrit must be checked at baseline and at 3 months; a rise above 54% (or to a level where erythrocytosis poses thrombotic risk) requires dose reduction or temporary discontinuation per the Endocrine Society guideline. [2]

The T-Trials (N=788) used a gel formulation titrated to achieve testosterone levels of 500 to 1 to 000 ng/dL. After 12 months, the sexual-function trial showed a statistically significant improvement in sexual desire (P<0.001) versus placebo, and the bone trial showed increased volumetric bone density at the spine (P<0.001). [4]

Patients must be counseled on transfer risk: gel contact with children or women can cause virilization. Hands should be washed thoroughly after application, and the application site should be covered with clothing before contact with others. [1]

Prostate-specific antigen (PSA) monitoring is required at 3 months and annually. Men with PSA above 4 ng/mL or a rise of more than 1.4 ng/mL over 12 months should be referred to urology before continuing therapy. [2]

Alaska-Specific Considerations for AndroGel Patients

Alaska's geography creates pharmacy access barriers that are clinically relevant. Approximately 60 rural communities in Alaska have no road access, meaning pharmacy supply depends on air freight. [19] AndroGel gel packets and pumps are not controlled-substance formulations requiring special courier handling beyond standard Schedule III chain-of-custody, so standard pharmacy mail-order is generally usable.

Cold storage is not required for AndroGel (store at 77 degrees Fahrenheit, excursions permitted to 59 to 86 degrees). [1] Alaska's cold winters do not degrade the product when stored indoors, but gel exposed to sustained freezing temperatures during shipping may be compromised. Patients receiving mail-order in rural areas should inspect packages for freeze-thaw damage.

Alaska has no state income tax and no state pharmacy benefit separate from Medicaid, so there are no Alaska-specific state subsidy programs for AndroGel beyond the federal Medicaid PDL and the federal 340B program (available to federally qualified health centers and tribal health organizations). [20] The Alaska Native Tribal Health Consortium and affiliated tribal health programs operate under 340B pricing, which may offer AndroGel or generic testosterone gel at substantially reduced rates for Alaska Native and American Indian patients.